Study: Diabetes complications in young children target the brain

February 10, 2021

JACKSONVILLE, Fla. (February 10, 2021) - Brain volume, verbal IQ, and overall IQ are lower in children with Type 1 diabetes (T1D) than in children without diabetes, according to a new longitudinal study published in Diabetes Care, a journal of the American Diabetes Association. The nearly eight-year study, led by Nelly Mauras, MD, a clinical research scientist at Nemours Children's Health System in Jacksonville, Florida, and Allan Reiss MD, a Professor at the Stanford University School of Medicine in California, compared brain scans of young children who have T1D with those of non-diabetic children to assess the extent to which glycemic exposure may adversely affect the developing brain.

"Our findings indicate that, despite improved glycemic control now possible with emerging technologies, individuals with T1D are at risk for cognitive dysfunction," said Mauras, principal investigator of the study, and Chief of the Division of Endocrinology, Diabetes & Metabolism at the Nemours Children's Health System in Jacksonville, Florida, and Professor of Pediatrics at the Mayo College of Medicine. "Our longitudinal data support the hypothesis that the brain is a target of diabetes complications in young children. Whether these changes can be reversed with scrupulous diabetes control requires further study."

The research team - from the Diabetes Research in Children Network (DirecNet), a multicenter National Institutes of Health-funded consortium - studied 144 children with T1D and 72 children without diabetes. Participating children had a median age of 7 years and average disease duration of 2.4 years when the study began. All study participants underwent structural magnetic resonance imaging (MRI) studies, as well as age-appropriate cognitive testing. In those with T1D, metabolic control was assessed using continuous glucose monitors (CGM) and hemoglobin A1C (HbA1C) testing. Over the eight-year study period, up to four MRIs were performed measuring white- and gray-matter volumes in various brain regions for all participants. In the T1D group, the research team assessed total cumulative hyperglycemic exposure since diagnosis.

The researchers found that total brain volume, gray- and white-matter volumes, overall IQ, and verbal IQ were lower in the diabetes group at 6, 8, 10, and 12 years, compared to controls. Differences at baseline persisted or increased over time, and brain volumes and cognitive scores declined as lifetime HbA1C index and higher sensor glucose rose.

"Although differences in cognition were mild - around 4 IQ points - this magnitude is similar to other conditions that affect the brain," said Mauras. "We know that T1D can cause complications in multiple organ systems, and our study adds knowledge to earlier research which suggested that glucose level variation in T1D can negatively affect brain development, beginning in childhood."

"It is truly important to follow-up on these results in two ways. The first is to study this and other populations of indiviudals with T1D into young adulthood to see if and how brain and cognitive issues affect long-term educational and vocational outcome. The second is to see if more rigorous early control of blood sugars can stop or even reverse the brain and cognitive effects we have observed in this study," said Reiss, co-principal investigator of the study and Robbins Professor and director, Division of Interdisciplinary Brain Sciences at the Stanford University School of Medicine.

Future research should examine whether improved diabetes control could possibly reverse the observed brain changes, and such studies also might follow individuals with T1D into young adulthood to see whether and how brain and cognitive issues affect long-term education and vocational outcomes.
The DirecNet consortium includes Nemours Children's Health System Jacksonville, Fla.; the Stanford University School of Medicine; Washington University, St Louis; University of Iowa; and Yale University.

This study was funded by the National Institute of Child Health and Development at the National Institutes of Health.

About Nemours Children's Health System

Nemours is an internationally recognized children's health system that owns and operates the Nemours Children's Specialty care in Jacksonville, FL, where the study was conducted, Nemours/Alfred I. duPont Hospital for Children in Wilmington, Del., and Nemours Children's Hospital in Orlando, Fla., along with outpatient facilities in six states, delivering pediatric primary, specialty and urgent care. Nemours also powers the world's most-visited website for information on the health of children and teens, and offers on-demand, online video patient visits through Nemours CareConnect.

Established as The Nemours Foundation through the legacy and philanthropy of Alfred I. duPont, Nemours provides pediatric clinical care, research, education, advocacy, and prevention programs to families in the communities it serves.


Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to